KERXKeryx Biopharmaceuticals (NASDAQ:KERX) announced the appointment of John F. Neylan, MD to the newly created position of Chief Medical Officer. In this role, Dr. Neylan will be responsible for oversight of medical affairs, clinical development and pharmacovigilence at Keryx.

“It is my pleasure to welcome John to Keryx,” said Greg Madison, President and Chief Operating Officer of Keryx. “As a nephrologist with extensive clinical development experience, John will be an invaluable member of the Keryx leadership team as we work to fulfill our vision of building a leading renal franchise.”

“I am honored to be joining an organization so clearly dedicated to improving the lives of those with kidney disorders,” said Dr. Neylan. “I look forward to working with my new colleagues as well as the many experts around the world who are helping to bring Auryxia™ (ferric citrate) to patients in need.”

Dr. Neylan is an accomplished nephrologist, transplantation specialist, and biopharmaceutical executive with broad-based experience in therapeutic development, from the preclinical phase to post-marketing development of therapies across primary care, specialty and rare disease indications. Dr. Neylan comes to Keryx from Genzyme Corporation, where since 2008 he served in the capacity of Senior Vice President, Clinical Development, focusing on specialty metabolic diseases. From 2000-2008, Dr. Neylan served as Vice President, Research and Development for Wyeth Research, overseeing the clinical development of transplantation therapeutics and providing medical affairs support to the transplant franchise.

Prior to joining industry, Dr. Neylan held prestigious positions in academia, including Professor of Medicine at Emory University and Assistant Professor of Medicine at UC Davis, serving at both institutions as Medical Director of the respective Renal Transplant Programs, with oversight of the clinical research programs. Dr. Neylan received his BS from Duke University and his MD from Rush Medical School in Chicago.  He completed his Internal Medicine residency at Vanderbilt University and fellowships in Nephrology and in Transplantation and Immunogenetics at Brigham and Women’s Hospital, Harvard University. Dr. Neylan has a proven track record for successful INDs, NDA/BLAs, and MAAs involving NCEs, polymers, biologics and RNA-based therapeutics and has authored more than 70 scientific manuscripts and book chapters.  He is Past-President of the American Society of Transplantation and past Board Member of the National Kidney Foundation, and a past Industry Representative on the FDA Cardiovascular and Renal Drugs Advisory Committee. (Original Source)

Shares of Keryx Biopharmaceuticals closed yesterday at $11.52. KERX has a 1-year high of $18.48 and a 1-year low of $10.85. The stock’s 50-day moving average is $12.69 and its 200-day moving average is $13.95.

On the ratings front, Keryx has been the subject of a number of recent research reports. In a report issued on April 20, Stifel Nicolaus analyst Stephen Willey reiterated a Buy rating on KERX, with a price target of $17, which implies an upside of 47.6% from current levels. Separately, on March 5, Roth Capital’s Joseph Pantginis reiterated a Buy rating on the stock and has a price target of $27.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Stephen Willey and Joseph Pantginis have a total average return of 40.2% and 13.7% respectively. Willey has a success rate of 67.4% and is ranked #25 out of 3577 analysts, while Pantginis has a success rate of 56.7% and is ranked #84.

In total, one research analyst has assigned a Hold rating and 6 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $11.52 which is 118.5% above where the stock closed yesterday.

Keryx Biopharmaceuticals Inc is a biopharmaceutical company focused on therapies for patients with renal disease. Its first product is the AuryxiaTM (ferric citrate), an oral, absorbable iron-based compound.